Other Events. On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. FTD is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs. Designated programs may benefit from more frequent interactions with the FDA and, if relevant criteria are met, may…

President, Research & Development — Charles S. Fuchs: The company hired a highly experienced external executive to lead R&D, signaling strategic investment in drug development capabilities.

Other Events. On July 13, 2026, Erasca, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 31,428,572 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at an offering pric…

Other Events. On July 13, 2026, Erasca, Inc. (the “Company”) announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Updated preliminary data from the Company’s ongoing AURORAS-1 Phase 1 trial in the U.S. builds on the Company’s April 2026 announcement, with additional patients and longer follow-up. Additional Results from AURORAS-1 Trial Encouraging Monotherapy Responses Observed in Second Line o…

Results of Operations and Financial Condition. On May 11, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of S…

Other Events. On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”). In the letter RevMed alleged that (1) the Company’s asset ERAS-0015 is “substantially equivalent” to certain compositions claimed in RevMed’s U.S. Patent No. 12,409,225 (the “‘225 Patent”) and that ERAS-0015 infringes the ‘225 Patent under the doctrine of equivalents; (2) that a third party misappropriated RevMed’s alleged trade secrets in connection with a patent relat…

Other Events. On April 21, 2026, Erasca, Inc. (the “Company”) narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no later than mid-May of 2026, from the prior guidance of the first half of 2026. The Company is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors, and the Company’s licensor, Guangzhou Joyo Pharmatech Co., Lt…

Results of Operations and Financial Condition. On March 12, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “fil…

Other Events. On January 20, 2026, Erasca, Inc. (the “Company”) disclosed that its cash, cash equivalents and marketable securities for the Company as of December 31, 2025 was approximately $341.8 million. On January 23, 2026, the Company announced that it closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares (the “January 2026 O…

Other Events. On January 21, 2026, Erasca, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 22,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at an offering p…

of this Form 8-K shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless otherwise expressly set forth by specific reference in such a filing. Forward-Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are f…

Other Events. On January 12, 2026, the Company announced clinical progress for its RAS-targeting franchise and 2026-2027 milestones. ERAS-0015 – Potential best-in-class RAS targeting molecule • Dose escalation in ongoing AURORAS-1 Phase 1 trial advancing faster than anticipated, due to significant unmet medical need and high investigator and patient enthusiasm • Ongoing confirmed and unconfirmed responses observed in multiple patients with differing tumor types and RAS mutations o Ongoing res…

Results of Operations and Financial Condition. On November 12, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purp…

Results of Operations and Financial Condition. On August 12, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of…

Results of Operations and Financial Condition. On May 13, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of S…

Results of Operations and Financial Condition. On March 20, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months and fiscal year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “fil…

Results of Operations and Financial Condition. On November 12, 2024, Erasca, Inc. announced its financial results for the three months ended September 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the…

Other Events. On October 24, 2024, Erasca, Inc. (the Company) announced preliminary data from its SEACRAFT-1 Phase 1b trial in an oral presentation at the 36 th EORTC-NCI-AACR (ENA) Symposium. In the Phase 1b trial of naporafenib plus trametinib (MEKINIST ® ) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations, the preliminary clinical activity of naporafenib plus trametinib in the melanoma cohort include, as of the efficacy cutoff dat…

Results of Operations and Financial Condition. On August 12, 2024, Erasca, Inc. announced its financial results for the three months ended June 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securit…

Other Events. On June 18, 2024, Erasca, Inc. (the Company) announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST ® ) in patients with NRAS-mutant melanoma. Stage 1 of this Phase 3 trial is expected to provide a randomized data readout of naporafenib plus trametinib against single agent trametinib in 2025. Cautionary Note Regarding Forward-Looking Statements Erasca cautions you tha…

Other Events. On May 16, 2024, Erasca, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 86,486,486 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) at an offering price of $1.85 per Share. The Underwriters have ag…

Entry into a Material Definitive Agreement. Joyo License Agreement On May 14, 2024, Erasca, Inc. (the “Company”) entered into an exclusive license agreement (the “Joyo License Agreement”) with Guangzhou Joyo Pharmatech Co., Ltd. (“Joyo”) under which the Company was granted an exclusive, worldwide (except mainland China, Hong Kong and Macau), royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Joyo to develop, manufacture, and commercialize c…

Costs Associated with Exit or Disposal Activities. On May 15, 2024, in connection with entering into the Joyo License Agreement and Medshine License Agreement, a review of the Company’s strategic priorities, and the Company’s decision to deemphasize certain drug discovery activities, the Company approved a strategic reprioritization to focus the Company’s resources on its naporafenib program, its product candidate ERAS-0015, which is the lead candidate from the Joyo License Agreement, and its…

Results of Operations and Financial Condition. On May 8, 2024, Erasca, Inc. announced its financial results for the three months ended March 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities…

Unregistered Sales of Equity Securities. The disclosures set forth in